
The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.

The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.
Download this White Paper to Learn More As the pharmaceutical landscape grows more competitive, launching…
California Walnut كما أظهر بحثٌ جديد أن تناول الجوز في وجبة الإفطار يمكن أن يحسّن…
Arab Newswire - Press release distribution to media in MENA/GCC Regions Newswire expands reach with…
News Ginkgo Bioworks has introduced the Virtual Cell Pharmacology Initiative (VCPI) through its Ginkgo Datapoints division, creating what it describes…
News Merge Labs has emerged from stealth with $252 million in funding to develop non-implantable brain–computer interfaces that use ultrasound…
Sarepta and Roche will share the monitors' findings with EMA to resolve a temporary hold. Elsewhere, Allakos agreed to a…
Prasad’s planned departure, expected at the end of April, culminates a tumultuous term in which he reworked vaccine guidelines and…
Sign in to your account